Skip to main content

Market Overview

Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US

  • Kindred Biosciences Inc (NASDAQ: KIN) has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture Center for Veterinary Biologics for review.
  • KIND-030 is a monoclonal antibody targeting canine parvovirus infection.
  • In September last year, Kindred Bio reported positive results from its pivotal efficacy study that showed a 60% mortality rate in the control dogs, compared to 0% in the KIND-030 treated dogs.
  • KIND-030 is being pursued for two indications in dogs - prophylactic therapy to prevent clinical signs of canine parvovirus infection, and treatment of established parvovirus infection.
  • The completion of the upcoming pivotal efficacy study for the treatment indication for KIND-030 is extended into the second quarter of 2021.
  • In December, Elanco Animal Health Inc (NYSE: ELANentered into an agreement with Kindred Biosciences to acquire exclusive global rights to KIND-030.
  • Price Action: KIN is down 0.4% at $4.71 in market trading hours on the last check Thursday.

Related Articles (ELAN + KIN)

View Comments and Join the Discussion!

Posted-In: parvovirusBiotech M&A News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at